Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 240 Rectal Neoplasms 93 Colonic Neoplasms 91 Pancreatic Neoplasms 87 Stomach Neoplasms 68 Neoplasm Metastasis 47 Esophageal Neoplasms 41 Neoplasms 36 Small Cell Lung Carcinoma 29 Lung Neoplasms 29 Neuroblastoma 28 Glioblastoma 28 Glioma 27 Brain Neoplasms 26 Carcinoma, Non-Small-Cell Lung 22 Adenocarcinoma Of Esophagus 20 Gliosarcoma 19 Breast Neoplasms 18 Astrocytoma 18 Esophageal Squamous Cell Carcinoma 17 Central Nervous System Neoplasms 17 Unspecified Adult Solid Tumor, Protocol Specific 16 Oligodendroglioma 13 Adenocarcinoma 13 Rhabdomyosarcoma 10 Gastrointestinal Neoplasms 10 Biliary Tract Neoplasms 10 Sarcoma 9 Gallbladder Neoplasms 9 Cholangiocarcinoma 9

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Irinotecan × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡